SCHEMBL4482739

SCHEMBL4482739

Cc1nc2cc(Cl)ccc2c(=O)o1

nearest known ligand 0.59

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ELANE P08246 6/20 0.59
C1R P00736 4/20 0.54
APEX1 P27695 1/20 0.54
ALDH1A1 P00352 5/20 0.51
MAPT P10636 3/20 0.51
POLB P06746 2/20 0.51
KDM4E B2RXH2 2/20 0.51
NPSR1 Q6W5P4 1/20 0.51
NR4A2 P43354 1/20 0.47
LMNA P02545 1/20 0.46
MPO P05164 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30089879 1.00 ELANE (0.59) ELANEC1RAPEX1ALDH1A1MAPT
SCHEMBL1812732 0.86 ELANE (0.70) ELANEC1RAPEX1ALDH1A1KDM4E
SCHEMBL31000399 0.86 ELANE (0.70) ELANEC1RAPEX1ALDH1A1KDM4E
SCHEMBL28961941 0.82 ELANE (0.74) ELANEC1RALDH1A1MAPTPOLB
SCHEMBL4891218 0.79 ELANE (0.59) ELANEALDH1A1MAPTPOLBKDM4E
SCHEMBL30089873 0.79 ELANE (0.59) ELANEC1RAPEX1ALDH1A1MAPT
SCHEMBL29701192 0.79 ELANE (0.59) ELANEALDH1A1MAPTPOLBKDM4E
SCHEMBL4113871 0.79 ELANE (0.59) ELANEC1RAPEX1ALDH1A1MAPT
SCHEMBL757536 0.79 ELANE (0.72) ELANEALDH1A1MAPTPOLBKDM4E
SCHEMBL6567259 0.78 C1R (0.52) ELANEC1RAPEX1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115521261-B Preparation method of mercapto-containing quinazolinone and composition thereof, and application of mercapto-containing quinazolinone in resisting kiwi fruit canker 贵州理工学院 2024-04-05 CN disclosed
CN-115521262-B Preparation method of quinazolinone containing phenyl and composition thereof, and application of quinazolinone and composition in resisting kiwi fruit canker 贵州理工学院 2024-04-05 CN disclosed
CN-115677803-A Preparation method of glucoside derivative containing quinazoline structure, preparation method of composition of glucoside derivative and application of composition in prevention and treatment of kiwifruit canker 贵州理工学院 2023-02-03 CN disclosed
CN-115521261-A Preparation method of sulfhydryl-containing quinazolinone and composition thereof and application of sulfhydryl-containing quinazolinone in resisting kiwifruit canker 贵州理工学院 2022-12-27 CN disclosed
CN-115521262-A Preparation method of phenyl-containing quinazolinone and composition thereof and application of phenyl-containing quinazolinone in resisting kiwifruit canker 贵州理工学院 2022-12-27 CN disclosed
EP-1717230-B1 FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE MSD KK (JP) 2014-08-06 EP disclosed
US-8541488-B2 Formed resin article and polymer film FUJIFILM CORPORATION (JP) 2013-09-24 US disclosed
US-8541488-B2 Formed resin article and polymer film FUJIFILM CORPORATION (JP) 2013-09-24 US disclosed
US-8268842-B2 Fused ring 4-oxopyrimidine derivative MSD K.K. (JP) 2012-09-18 US disclosed
US-20110186791-A1 ULTRAVIOLET ABSORBENT COMPOSITION FUJIFILM CORPORATION (JP) 2011-08-04 US disclosed
US-20110024701-A1 Ultraviolet Absorbent Composition FUJIFILM CORPORATION (JP) 2011-02-03 US disclosed
US-20110024701-A1 Ultraviolet Absorbent Composition FUJIFILM CORPORATION (JP) 2011-02-03 US disclosed
US-20100004439-A1 Heterocyclic Compound FUJIFLM CORPORATION (JP) 2010-01-07 US disclosed
US-20100004439-A1 Heterocyclic Compound FUJIFLM CORPORATION (JP) 2010-01-07 US disclosed
US-20090239982-A1 Ultraviolet Absorbent and Heterocyclic Compound FUJIFILM CORPORATION (JP) 2009-09-24 US disclosed
US-20090239982-A1 Ultraviolet Absorbent and Heterocyclic Compound FUJIFILM CORPORATION (JP) 2009-09-24 US disclosed
US-20090209562-A1 Fused ring 4-oxopyrimidine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-08-20 US disclosed
US-7521455-B2 Fused ring 4-oxopyrimidine derivative BANYU PHARMACEUTICAL CO. LTD. (JP) 2009-04-21 US disclosed
EP-1717230-A1 FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-02 EP disclosed
US-20050182045-A1 Fused ring 4-oxopyrimidine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239982-A1 Ultraviolet Absorbent and Heterocyclic Compound CYP2A6, CYP2B6, XPO6 ELANE 1479/4885C1R 520/4885APEX1 366/4885
US-20050182045-A1 Fused ring 4-oxopyrimidine derivative HRH4, HRH2, HRH3 ELANE 4447/4885C1R 472/4885APEX1 4021/4885
US-20090209562-A1 Fused ring 4-oxopyrimidine derivative HRH4, HRH2, HRH3 ELANE 4447/4885C1R 472/4885APEX1 4021/4885
US-20100004439-A1 Heterocyclic Compound PTGER1, CYP1A1, ALOX12 ELANE 1343/4885C1R 959/4885APEX1 567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.